Imaging Techniques to Determine Degree of Sarcopenia and Systemic Inflammation in Advanced Renal Cell Carcinoma.

IF 2.5 2区医学 Q2 UROLOGY & NEPHROLOGY

Current Urology Reports Pub Date : 2023-07-01 DOI:10.1007/s11934-023-01157-6

Benjamin N Schmeusser, Adil A Ali, Florian J Fintelmann, Jose M Garcia, Grant R Williams, Viraj A Master, Sarah P Psutka

{"title":"Imaging Techniques to Determine Degree of Sarcopenia and Systemic Inflammation in Advanced Renal Cell Carcinoma.","authors":"Benjamin N Schmeusser, Adil A Ali, Florian J Fintelmann, Jose M Garcia, Grant R Williams, Viraj A Master, Sarah P Psutka","doi":"10.1007/s11934-023-01157-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: The purpose of this review is to provide an up-to-date understanding regarding the literature on sarcopenia and inflammation as prognostic factors in the context of renal cell carcinoma (RCC).Recent findings: Sarcopenia is increasingly recognized as a prognostic factor in RCC. Emerging literature suggests monitoring quantity of muscle on successive imaging and examining muscle density may be additionally informative. Inflammation has prognostic ability in RCC and is also considered a key contributor to development and progression of both RCC and sarcopenia. Recent studies suggest these two prognostic factors together may provide additional prognostic ability when used in combination. Ongoing developments include quality control regarding sarcopenia research and imaging, improving understanding of muscle loss mechanisms, and enhancing clinical incorporation of sarcopenia via improving imaging analysis practicality (i.e., artificial intelligence) and feasible biomarkers. Sarcopenia and systemic inflammation are complementary prognostic factors for adverse outcomes in patients with RCC. Further study on high-quality sarcopenia assessment standardization and expedited sarcopenia assessment is desired for eventual routine clinical incorporation of these prognostic factors.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330545/pdf/nihms-1900776.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Urology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11934-023-01157-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Purpose of review: The purpose of this review is to provide an up-to-date understanding regarding the literature on sarcopenia and inflammation as prognostic factors in the context of renal cell carcinoma (RCC).

Recent findings: Sarcopenia is increasingly recognized as a prognostic factor in RCC. Emerging literature suggests monitoring quantity of muscle on successive imaging and examining muscle density may be additionally informative. Inflammation has prognostic ability in RCC and is also considered a key contributor to development and progression of both RCC and sarcopenia. Recent studies suggest these two prognostic factors together may provide additional prognostic ability when used in combination. Ongoing developments include quality control regarding sarcopenia research and imaging, improving understanding of muscle loss mechanisms, and enhancing clinical incorporation of sarcopenia via improving imaging analysis practicality (i.e., artificial intelligence) and feasible biomarkers. Sarcopenia and systemic inflammation are complementary prognostic factors for adverse outcomes in patients with RCC. Further study on high-quality sarcopenia assessment standardization and expedited sarcopenia assessment is desired for eventual routine clinical incorporation of these prognostic factors.

Abstract Image

查看原文本刊更多论文

影像学技术测定晚期肾细胞癌中肌肉减少和全身性炎症程度。

综述的目的:本综述的目的是提供关于骨骼肌减少症和炎症作为肾细胞癌(RCC)预后因素的最新文献。最近发现:肌少症越来越被认为是肾细胞癌的一个预后因素。新出现的文献表明，在连续成像中监测肌肉数量和检查肌肉密度可能会提供额外的信息。炎症在肾小细胞癌中具有预后能力，也被认为是肾小细胞癌和肌肉减少症发生和发展的关键因素。最近的研究表明，这两个预后因素在一起使用时可能提供额外的预后能力。正在进行的发展包括对肌少症研究和成像的质量控制，提高对肌肉损失机制的理解，以及通过提高成像分析的实用性(即人工智能)和可行的生物标志物来加强肌少症的临床结合。肌肉减少症和全身性炎症是RCC患者不良结局的互补预后因素。需要进一步研究高质量的肌肉减少症评估标准化和快速的肌肉减少症评估，以便最终将这些预后因素纳入常规临床。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Urology Reports UROLOGY & NEPHROLOGY-

CiteScore

4.60

自引率

3.80%

发文量

期刊介绍： This journal intends to review the most important, recently published findings in the field of urology. By providing clear, insightful, balanced contributions by international experts, the journal elucidates current and emerging approaches to the care and prevention of urologic diseases and conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as benign prostatic hyperplasia, erectile dysfunction, female urology, and kidney disease. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.